Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 1652931, 14 pages
https://doi.org/10.1155/2017/1652931
Research Article

Renal Transplant Patients Biopsied for Cause and Tested for C4d, DSA, and IgG Subclasses and C1q: Which Humoral Markers Improve Diagnosis and Outcomes?

1VRL Eurofins, Los Angeles, CA, USA
2MNIT Foundation, Los Angeles, CA, USA
3USC Keck School of Medicine, Los Angeles, CA, USA
4Western University of Health Sciences, Pomona, CA, USA
5University of Miami, Miami, FL, USA
6BloodSource, Mather, CA, USA
7UC Davis School of Medicine, Sacramento, CA, USA
8CNSU College of Medicine, Elk Grove, CA, USA
9St. Vincent Medical Center, Los Angeles, CA, USA
10Transplant Research Institute, Los Angeles, CA, USA

Correspondence should be addressed to Nathan A. Lemp; moc.sniforue-lrv@pmelnahtan

Received 3 October 2016; Accepted 5 December 2016; Published 15 January 2017

Academic Editor: Frans H. J. Claas

Copyright © 2017 James C. Cicciarelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. I. Terasaki, “Humoral theory of transplantation,” American Journal of Transplantation, vol. 3, no. 6, pp. 665–673, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. D. N. Chakravarti, R. D. Campbell, and R. R. Porter, “The chemical structure of the C4d fragment of the human complement component C4,” Molecular Immunology, vol. 24, no. 11, pp. 1187–1197, 1987. View at Publisher · View at Google Scholar · View at Scopus
  3. H. E. Feucht, E. Felber, M. J. Gokel et al., “Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection,” Clinical and Experimental Immunology, vol. 86, no. 3, pp. 464–470, 1991. View at Publisher · View at Google Scholar · View at Scopus
  4. H. E. Feucht, H. Schneeberger, G. Hillebrand et al., “Capillary deposition of C4d complement fragment and early renal graft loss,” Kidney International, vol. 43, no. 6, pp. 1333–1338, 1993. View at Publisher · View at Google Scholar · View at Scopus
  5. P. F. Halloran, J. Schlaut, K. Solez, and N. S. Srinivasa, “The significance of the anti-class I response II. Clinical and pathologic features of renal transplants with anti-class i-like antibody,” Transplantation, vol. 53, no. 3, pp. 550–555, 1992. View at Publisher · View at Google Scholar · View at Scopus
  6. J. C. Scornik, D. R. Salomon, P. B. Lim, R. J. Howard, and W. W. Pfaff, “Posttransplant antidonor antibodies and graft rejection. Evaluation by two-color flow cytometry,” Transplantation, vol. 47, no. 2, pp. 287–290, 1989. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Suciu-Foca, E. Reed, C. Marboe et al., “The role of anti-HLA antibodies in heart transplantation,” Transplantation, vol. 51, no. 3, pp. 716–724, 1991. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Solez, R. A. Axelsen, H. Benediktsson et al., “International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology,” Kidney International, vol. 44, no. 2, pp. 411–422, 1993. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Patel and P. I. Terasaki, “Significance of the positive crossmatch test in kidney transplantation,” New England Journal of Medicine, vol. 280, no. 14, pp. 735–739, 1969. View at Publisher · View at Google Scholar · View at Scopus
  10. J. C. Scornik, W. M. Lefor, J. C. Cicciarelli et al., “Hyperacute and acute kidney graft rejection due to antibodies against B cells,” Transplantation, vol. 54, no. 1, pp. 61–64, 1992. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Mauiyyedi, M. Crespo, A. Bernard Collins et al., “Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification,” Journal of the American Society of Nephrology, vol. 13, no. 3, pp. 779–787, 2002. View at Google Scholar · View at Scopus
  12. M.-L. Arnold, I.-S. Ntokou, I. I. N. Doxiadis, B. M. Spriewald, J. N. Boletis, and A. G. Iniotaki, “Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies,” Transplant International, vol. 27, no. 3, pp. 253–261, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Khovanova, S. Daga, T. Shaikhina et al., “Subclass analysis of donor HLA-specific IgG in antibody-incompatible renal transplantation reveals a significant association of IgG4 with rejection and graft failure,” Transplant International, vol. 28, no. 12, pp. 1405–1415, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Hönger, H. Hopfer, M.-L. Arnold, B. M. Spriewald, S. Schaub, and P. Amico, “Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection,” Transplantation, vol. 92, no. 1, pp. 41–47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Kaneku, J. G. O'Leary, M. Taniguchi, B. M. Susskind, P. I. Terasaki, and G. B. Klintmalm, “Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with Chronic rejection and graft loss after liver transplantation,” Liver Transplantation, vol. 18, no. 8, pp. 984–992, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. J. C. Cicciarelli, N. Kasahara, N. A. Lemp et al., “Immunoglobulin G subclass analysis of HLA donor specific antibodies in heart and renal transplant recipients,” Clinical Transplantation, pp. 413–422, 2013. View at Google Scholar
  17. C. Lefaucheur, D. Viglietti, C. Bentlejewski et al., “IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury,” Journal of the American Society of Nephrology, vol. 27, no. 1, pp. 293–304, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Lowe, R. Higgins, D. Zehnder, and D. C. Briggs, “Significant IgG subclass heterogeneity in HLA-specific antibodies: implications for pathogenicity, prognosis, and the rejection response,” Human Immunology, vol. 74, no. 5, pp. 666–672, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Alberu, M. I. Vargas-Rojas, L. E. Morales-Buenrostro et al., “De novo donor-specific hla antibody development and peripheral CD+CD25high cells in kidney transplant recipients: a place for interaction?” Journal of Transplantation, vol. 2012, Article ID 302539, 8 pages, 2012. View at Publisher · View at Google Scholar
  20. J. E. Cooper, J. Gralla, L. Chan, and A. C. Wiseman, “Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts,” Clinical Transplantation, pp. 359–364, 2011. View at Google Scholar
  21. J. M. DeVos, S. J. Patel, K. M. Burns et al., “De novo donor specific antibodies and patient outcomes in renal transplantation,” Clinical Transplantation, pp. 351–358, 2011, https://www.ncbi.nlm.nih.gov/pubmed/22755430.
  22. F. Ginevri, A. Nocera, P. Comoli et al., “Posttransplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection,” American Journal of Transplantation, vol. 12, no. 12, pp. 3355–3362, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Hourmant, A. Cesbron-Gautier, P. I. Terasaki et al., “Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation,” Journal of the American Society of Nephrology, vol. 16, no. 9, pp. 2804–2812, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Wiebe, I. W. Gibson, T. D. Blydt-Hansen et al., “Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant,” American Journal of Transplantation, vol. 12, no. 5, pp. 1157–1167, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Eskandary, G. Bond, N. Kozakowski et al., “Diagnostic contribution of donor-specific antibody characteristics to uncover late silent antibody-mediated rejection-results of a cross-sectional screening study,” Transplantation, 2016. View at Publisher · View at Google Scholar
  26. M. Willicombe, P. Brookes, R. Sergeant et al., “De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy,” Transplantation, vol. 94, no. 2, pp. 172–177, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. C. L. Klein and D. C. Brennan, “C4d staining in renal allografts and treatment of antibody-mediated rejection,” 2016, http://www.uptodate.com/contents/c4d-staining-in-renal-allografts-and-treatment-of-antibody-mediated-rejection.
  28. H. E. Feucht and G. Opelz, “The humoral immune response towards HLA class II determinants in renal transplantation,” Kidney International, vol. 50, no. 5, pp. 1464–1475, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Nishi, N. Imai, Y. Ito et al., “Pathological study on the relationship between C4d, CD59 and C5b-9 in acute renal allograft rejection,” Clinical Transplantation, Supplement, vol. 18, no. s11, pp. 18–23, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Asgari, W. Zhou, and S. Sacks, “Complement in organ transplantation,” Current Opinion in Organ Transplantation, vol. 15, no. 4, pp. 486–491, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. I. G. A. Bos, I. J. M. Ten Berge, and C. E. Hack, “Role of complement in graft rejection after organ transplantation,” Transfusion Medicine Reviews, vol. 16, no. 3, pp. 251–264, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Loupy, C. Lefaucheur, D. Vernerey et al., “Complement-binding anti-HLA antibodies and kidney-allograft survival,” New England Journal of Medicine, vol. 369, no. 13, pp. 1215–1226, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Yell, B. L. Muth, D. B. Kaufman, A. Djamali, and T. M. Ellis, “C1q binding activity of de novo donor-specific HLA antibodies in renal transplant recipients with and without antibody-mediated rejection,” Transplantation, vol. 99, no. 6, pp. 1151–1155, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. J. G. O'Leary, H. Kaneku, N. Banuelos, L. W. Jennings, G. B. Klintmalm, and P. I. Terasaki, “Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation,” American Journal of Transplantation, vol. 15, no. 4, pp. 1003–1013, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. H. G. Otten, M. C. Verhaar, H. P. E. Borst, R. J. Hené, and A. D. V. Zuilen, “Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure,” American Journal of Transplantation, vol. 12, no. 6, pp. 1618–1623, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Fujita, M. B. Soyka, M. Akdis, and C. A. Akdis, “Mechanisms of allergen-specific immunotherapy,” Clinical and Translational Allergy, vol. 2, no. 1, article no. 2, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Burns, T. Whitted, J. C. Cicciarelli, N. A. Lemp, E. Klohe, and Y. Chang, “C1Q single antigen bead testing: a case with questionable significance?” in Proceedings of the 42nd Meeting of the American Society for Histocompatibility and Immunogenetics (ASHI '16), St. Louis, Mo, USA, September 2016.